Phase 3 study of UX007 in patients with Long-Chain Fatty Acid Oxidation Disorder
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Triheptanoin (Primary)
- Indications Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 02 Nov 2017 According to an Ultragenyx media release, the company continue to plan for discussions with regulators regarding the study by the end of 2017.
- 27 Jul 2017 According to Ultragenyx media release, the company continue to plans for discussion with the regulatory authorities.
- 15 Oct 2015 New trial record